--- title: "U.S. stock market midday update: Twist up 9.53%: AI pharmaceutical leader in demand, funds pouring in to boost stock price" type: "News" locale: "en" url: "https://longbridge.com/en/news/296944224.md" description: "Twist Bioscience rose 9.53%; Moderna rose 13.12%, with a transaction volume of USD 5.273 billion; Amgen rose 0.17%, with a transaction volume of USD 490 million; Natera rose 1.85%, with a transaction volume of USD 366 million; AbbVie rose 0.61%, with a market value of USD 470.3 billion" datetime: "2026-08-25T17:37:55.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296944224.md) - [en](https://longbridge.com/en/news/296944224.md) - [zh-HK](https://longbridge.com/zh-HK/news/296944224.md) generator: "portal-rs" --- # U.S. stock market midday update: Twist up 9.53%: AI pharmaceutical leader in demand, funds pouring in to boost stock price **U.S. Stock Market Midday Update** Twist Bioscience rose 9.53%. Based on recent key news: 1. On August 25, Twist Bioscience's stock price increased primarily due to its irreplaceable position in the electrification ecosystem. The company is addressing computing, spatial, and energy bottlenecks, rebuilding industry barriers, and driving up stock prices. 2. On August 25, increased market interest in derivatives attracted more investors to Twist Bioscience as a mature underlying asset, leading to a rise in stock prices. 3. On August 25, the complexity of the technology cycle positioned Twist Bioscience significantly within the industry, further enhancing market confidence in it. The increasing complexity of the tech industry has led to significant capital inflows. **Stocks with High Trading Volume in the Industry** Moderna rose 13.12%. Based on recent key news: 1. On August 24, Moderna and Merck jointly announced that their personalized mRNA cancer vaccine achieved its primary endpoint in a Phase III clinical trial for melanoma patients, marking the first positive late-stage clinical data for an mRNA cancer vaccine, significantly boosting stock prices. Source: Benzinga 2. On August 24, Huafu Securities released a research report stating that Moderna and Merck's personalized tumor vaccine achieved its primary endpoint in a Phase III study for postoperative adjuvant melanoma, reducing the risk of recurrence or death by 49%, marking a significant breakthrough in tumor treatment paradigms and further boosting market confidence. Source: Global Times Finance 3. On August 24, Barclays raised Moderna's target price, optimistic about the transformative potential of its melanoma vaccine, leading to a rise in stock prices. Source: Benzinga The pharmaceutical sector continues to strengthen, focusing on the tumor vaccine field. Amgen rose 0.17%, with increased trading volume. Based on recent key news: 1. On August 25, market analysis indicated that although Amgen is currently rated as a hold by analysts, top analysts believe there are five stocks more worthy of purchase, which may affect investor confidence and lead to stock price fluctuations. 2. On August 25, the FDA is reviewing Amgen's applications for full approval of two therapies, a development that could positively impact the company's future revenue and boost stock prices. 3. On August 26, Amgen's annualized return over the past 15 years was 14.92%, demonstrating long-term investment value, which may attract long-term investors and support stock prices. The biotechnology industry faces regulatory challenges. Natera rose 1.85%. Based on recent key news: 1. On August 25, Natera reported a 37.7% year-over-year increase in second-quarter revenue, with net losses narrowing to $67 million and gross margin improving to 64.5%. The company raised its full-year revenue guidance to $2.85 billion to $2.91 billion, with the tumor detection product Signatera surpassing 280,000 tests in a single quarter, driving performance above expectations Multiple investment banks have raised their target prices, with Citigroup increasing its target price from $315 to $365 while maintaining a buy rating; Morgan Stanley's target price is $355, and Canaccord Genuity has set it at $375. Additionally, Stanley Druckenmiller's Duquesne family office has listed Natera as its top holding, further boosting market confidence. Source: Zhitong Finance On August 25, Natera reached a collaboration with Kupando Therapeutics to provide Latitude ctDNA testing services for its Phase I clinical trial for skin cancer, expanding the application scenarios of its products. Source: Zhitong Finance The overall industry performance is strong, with significant capital inflows. **Stocks ranked at the top of the industry by market capitalization** AbbVie rose by 0.61%. Based on recent news, On August 24, AbbVie rose over 1% in pre-market trading, reaching a historic high. Fifth Third Bancorp reduced its AbbVie holdings by 2.1% in the second quarter, retaining 2.15 million shares valued at $541.38 million. Analysts maintain a consensus rating of "moderate buy," with an average target price of $275.95. Positive lung cancer data and updates on beauty product pipelines have positively impacted the stock price. On August 25, ample capital reserves are being translated into definitive clinical execution capabilities. The global Phase III clinical study of Tofacitinib for generalized myasthenia gravis is progressing, and the global Phase III clinical study for primary Sjögren's syndrome has also entered the patient recruitment stage. The progress of clinical research brings positive expectations for the company's future market space. On August 25, Rongchang Biologics announced its interim performance, with product sales, R&D services, and licensing revenue amounting to approximately 5.85 billion yuan, a year-on-year increase of 435.74%. An exclusive licensing agreement was signed with AbbVie, granting AbbVie exclusive rights for the development, production, and commercialization of RC148 outside the Greater China region, significantly increasing technology licensing revenue. The overall industry is performing well, and clinical research is progressing smoothly ### Related Stocks - [TWST.US](https://longbridge.com/en/quote/TWST.US.md) - [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) - [NTRA.US](https://longbridge.com/en/quote/NTRA.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) ## Related News & Research - [Twist Bioscience (TWST) Stock Looks Undervalued On Cash Flow But Overvalued On Sales](https://longbridge.com/en/news/298517695.md) - [Twist Bioscience CEO, CFO to speak at Baird Global Healthcare Conference fireside chat](https://longbridge.com/en/news/298454186.md) - [Allianz Asset Management GmbH Buys New Position in Twist Bioscience Corporation $TWST](https://longbridge.com/en/news/298550224.md) - [Susquehanna Fundamental Investments LLC Takes Position in Twist Bioscience Corporation $TWST](https://longbridge.com/en/news/297631371.md) - [Twist Bioscience Registers Invenra Share Resale Prospectus](https://longbridge.com/en/news/296408832.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**